Category: Cancer Treatment

Oncotarget: Taking the Lead in Scientific Information

Since time immemorial, the scientific world has always been driven by research and development. Despite this truth, it is still difficult finding credible sources for your scientific research. Not anymore! Oncotarget, a weekly peer review journal founded in 2010 seeks to change this by making credible scientific information not only accessible but also free for all.

It is an online publication that was founded by the chief editor Mr. Mikhail Blagosklonny alongside his colleague Andrei V. Gudkov and sort to address the area of oncology. The two senior editors who are also top researchers when it comes to the field of cancer and aging sort to provide credible information on the subject of oncology that would not only help in research but also improve the living standards of individuals. The success of this online publication, however, saw the editors include additional section to their publication including immunology and microbiology, autophagy, gerotarget, Chromosome and Cell Death to name but a few and read full article.

Oncotarget publication has been quite resourceful in a number of ways. First, it has contributed to the growth of scientific information by making the work of accessing information less complicated. Unlike in the past, you can now easily find the information you are looking for in a faster and easier manner through the Oncotarget’s website. Secondly, it provides researchers with a platform to share and have their research published. Once your research findings pass the credibility test, you will only pay a little fee to have your findings published and learn more about Oncotarget.

So far, the progress made by Oncotarget is quite recommendable. Mr. Mikhail Blagosklonny a key figure in the oncology world and the leading editor of this publication has made sure that his readers settle for nothing short of quality. In addition to leading the team of editors, he has also contributed towards the information build up by authoring more than 250 journals that can be found on the Oncortarget’s website. Arguably, some of his famous works include Cell Death Differ, Cancer Res, Autophagy and Cancer Biol Ther and Oncotarget on Facebook.

As we continue relying on scientific information and data to combat some of the world’s chronic conditions, we can always count on the continued commitment of Oncotarget publication to get us to our destination and Oncotarget’s lacrosse camp.

More Visit: https://www.researchgate.net/journal/1949-2553_Oncotarget

Dr. Clay Siegall: A Leader In Innovative Cancer Treatment Methods

Dr. Clay Siegall is passionate about cancer research. He has been for over two decades. After working for some of the world’s best known cancer research companies, he co-founded Seattle Genetics in 1998. The company quickly became a world leader in the development of targeted cutting-edge cancer treatment. ADCETRIS, the antibody-drug conjugate it developed, is used worldwide to help cancer patients. The company also has a number of other viable cancer treatments that it has licensed to several major biotech companies. These drugs have made the company hundreds of millions of dollars.

Since graduating with a PhD in genetics from George Washington University, Clay Siegall has developed a reputation for creating very effective cancer treatments. It is a goal he set for himself ever since he was a teen. Now at Seattle Genetics has a team of researchers that have made a number of very important breakthroughs in cancer care. Their ability to create drugs that kill cancerous cell without harming surrounding tissue has made them world-famous and led to their products being in great demand. It has also made Seattle Genetics founder, president and CEO Clay Siegal world famous.

Dr. Siegall is motivated by his desire to end the suffering cancer patients are forced to endure when they receive treatment. Many of the treatment methods commonly used leave patients weakened and writhing in pain. But the staff at Seattle Genetics is committed to developing treatments that are more effective and less painful. Their work is transforming cancer treatment and creating hope for people suffering with the debilitating disease. Under the guidance of Dr. Siegall they have made great strides in developing treatment methodologies that provide relief for patients with cancer.

A major role Dr. Siegal plays at Seattle Genetics is in fundraising. So far he has been able to use public and private sources to generate over $1.2 billion for the company. This has enabled the staff at Seattle Genetics to purchase the technology they need to remain in the forefront of the development of new treatments for cancer and bring relief for countless people worldwide suffering with cancer.